IL23A and autoimmune disease: Ustekinumab and other anti-IL23p19 inhibitors have been highly effective for the treatment of autoimmune disease; however, these treatments are not without issues, which include the reliance on administration by subcutaneous injection and immunogenicity (Jullien et al., 2015).